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SUMMARY
The aim of this study is to re-evaluate urinary collagen cross-links, previously proposed as markers of osteoarthritis (OA). The
urinary excretion of collagen cross-links, pyridinoline (PYD) and deoxypyridinoline (DPD), was measured using
high-performance liquid chromatography (HPLC) in 114 patients with OA, 19 patients with rheumatoid arthritis (RA) and 40
healthy subjects. An increase in PYD and DPD, expressed per millimole of creatinine, was confirmed in RA. However, PYD
and DPD in patients with hip OA, knee OA and polyOA were similar, and did not differ from controls. In patients with
radiographic end-stage OA, PYD and DPD were significantly higher than in patients with an early OA, but not significantly
higher than in controls. The PYD/DPD ratio did not vary with the OA stage. Thus, urinary collagen cross-links are not elevated
in OA, but could reflect bone sclerosis and/or erosion in late OA.
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THE covalent bridges or cross-links between the
adjacent molecules of collagen stabilize the extracellu-
lar matrix of connective tissues. Owing to their natural
fluorescent properties, the pyridinium cross-links,
pyridinoline (PYD) and deoxypyridinoline (DPD),
have been identified in many connective tissues,
essentially in bone and cartilage [1, 2]. DPD is mostly
found in bone, while PYD is found both in skeletal
and vascular connective tissues [1, 3]. Unlike hydroxy-
proline, pyridinium cross-links are released following
mature collagen degradation in peptide-free forms
and are excreted unchanged in urine. Pyridinium
cross-links are measured by high-performance liquid
chromatography (HPLC), paper chromatography
and enzyme-linked immunoassay (ELISA) [4]. Both
paper chromatography and ELISA do not allow PYD
and DPD to be distinguished. Quantitative analysis
using ion-paired reversed-phase liquid chromato-
graphy followed by fluorescent detection has been
improved [5].
Pyridinium cross-links have already been proposed
as an index of bone resorption in Paget's disease [6],
primary hyperparathyroidism [7], bone metastasis [8]
and osteoporosis [9]. PYD and DPD were also
investigated in osteoarthritis (OA) and rheumatoid
arthritis (RA). They were suggested as markers of joint
degradation [10-15]. These studies led us to correlate
urinary pyridinium cross-links with the measurement
of joint space narrowing in patients with hip OA [16].
However, initial results obtained in such patients
clearly conflicted with reported studies. The present
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work is a re-evaluation of urinary concentrations of
pyridinium cross-links in OA patients.
PATIENTS AND METHODS
Patients
The OA group was made up of 114 consecutive
patients, referred to the rheumatology clinic for
symptomatic OA. There were 47 hip OA (coxOA), 31
knee OA (gonOA) and 36 patients with generalized OA
(polyOA). All these patients fulfilled the ACR criteria
for OA [17]. A normal control group was composed of
40 healthy volunteers. A joint disease control group
was composed of 19 patients with classic RA,
according to the ARA criteria. Age, sex, menopausal
status, weight and body mass index are given in
Table I.
Anteroposterior roentgenograms of lumbar rachis,
pelvis and knees taken in the weight-bearing position,
a sunrise view of the patellofemoral joints and dorsal
X-ray of the hands were performed in OA patients and
normal controls. Films were read by a single
experienced observer who was blinded to the patient's
status. X-ray OA was scored as follows: stage 1,
minimal joint space loss and/or osteophytosis; stage 2,
substantial but incomplete joint space loss; stage 3,
total and focal joint space narrowing; stage 4, nearly
complete joint space narrowing and subchondral bone
erosion (intraobserver reproducibility: k = 0.76) [18].
In patients with bilateral OA, the most severely affected
side was analysed.
Westergren erythrocyte sedimentation rate (ESR)
(mm/h), routine blood haematology and biochemistry
tests (red and white cell counts, alkaline phosphatase,
alanine aminotransferase, calcium, phosphorus, gly-
caemia, albumin and creatinine) were performed in OA
and RA patients. None of the patients suffered from
renal impairment, diabetes or a metabolic bone disease.
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OA
RA
Characteristics
JV
40
114
19
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TABLE I
of patients with osteoarthritis (OA), rheumatoid arthritis (RA) and
Age
42.9 (12)
62.44(11.5)
58.3 (18)
Weight
70.56 (13.4)
73.72 (12.5)
66.67 (15)
BMI
24.37 (4.2)
27.74 (4.2)
24.75 (4)
NO. 11
controls (median
Sex ratio
M/F
21/19
49/65
8/11
andiD.)
Post-menopausal/
non-post-menopausal
9/10
50/15
7/4
Measurement of urinary pyridinoline and deoxypyridino-
line
Morning urine samples were collected from all
patients and stored at — 20°C prior to analysis. Urine
samples were centrifuged at 1000 g during 10 min and
an aliquot of urine was hydrolysed by heating with an
equal volume of 12 M HC1 at 116°C during 16 h, to
convert all cross-links to the free form. The hydro-
lysates were fractionated by partition chromatography
on CFl cellulose and the pyridinium compounds were
quantified by reverse-phase, isocratic, ion-paired
HPLC as described by James et al. [19]. The ion-pairing
agent used was the octane sulphonic acid. Concen-
trations of urinary pyridinium cross-links were
expressed relative to values of urinary creatinine
(nmol/mmol Cr). The coefficient of variation of the
PYD and DPD assay was 14 and 15%, respectively.
Statistical analysis
A comparison between two groups was performed
using Student's f-test. Analysis of variance was used
when there were more than two groups. Correlations
were studied using simple linear regression.
RESULTS
Figure 1 shows the individual values of PYD and
DPD for each group. Means and standard deviations
according to age and sex are given in Table II. PYD
and DPD excretion, as well as the PYD/DPD ratio,
were unrelated to sex, age, menopausal status, weight
or body mass index (BMI) in each of the control,
OA and RA groups. In healthy control individuals,
mean values and standard deviations of PYD and
DPD/mmol of creatinine were 34.5 ± 4.9 and
6.9 ± 1.1 nmol/mmol, respectively. The PYD/DPD
ratio was 8.1 ± 1.9 nmol/mmol. The strong correlation
between PYD and DPD (r = 0.76; /> < 0.001) is
illustrated in Fig. 2.
Urinary concentrations of PYD and DPD in OA
patients were slightly but not significantly lower than
those in the control group (30.2 ±1.7 and
6.2 ± 0.4 nmol/mmol, respectively). The PYD/DPD
ratio was unmodified in OA (5.5 ± 0.2 nmol/mmol).
PYD was sometimes increased in polyOA, but no
significant difference was found between patients with
hip OA, knee OA and polyOA (Fig. 3). Urinary
concentrations of hydroxypyridinium cross-links ac-
cording to radiographic scores were studied in patients
with hip or knee OA. They clearly increased with
radiographic scores, but the difference between the four
groups was not significant. When pooling patients with
early OA (X-ray score 1 and 2) and patients with late
OA (X-ray score 3 and 4), PYD and DPD were,
respectively, 1.47- and 1.4-fold higher in late OA than
in early OA (P = 0.003 and 0.04, respectively) (Fig. 4).
The PYD/DPD ratios were 4.4 ± 1.3 and 6.1 ±2.7,
respectively. The urinary excretion of PYD and DPD
was unrelated to NSAID uptake.
PYD and DPD were increased by 42.5 and 29.7%,
respectively, in RA patients, when compared with
normal controls. The difference was significant
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FIG. I.—Urinary concentrations of pyridinoline (PYD) (a) and
deoxypyridinoline (DPD) (b) in patients with osteoarthritis (OA) and
rheumatoid arthritis (RA) and controls. All concentrations are
expressed relative to urinary creatinine.
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TABLE II
Pyridinium cross-link values (median and S.D.) in patients with osteoarthritis (OA), rheumatoid arthritis (RA) and controls relative to sex and
menopausal status. Values are expressed relative to urinary creatinine
Controls OA RA
PYD DPD
(nmol/mmol) (nmol/mmol)
PYD DPD
N (nmol/mmol) (nmol/mmol)
PYD DPD
N (nmol/mmol) (nmol/mmol)
Males
Non-post-menopausal
females
Post-menopausal females
Total
21
10
9
40
33.77 ±3.9 6.71 ± 1.9 49 27.45 ± 2.2 4.9 ± 0.4 8 47.61 ± 3.9 8.58 ± 1.6
32.86 ± 6.6
37.78 ± 8.6
34.5 ± 4.9
7.89 ± 2.4
6.34 ± 1.9
6.92 ± 1.1
15
50
114
22.9 ±2.1
33.17 ±2.8
30.17 ± 1.7
4.9 ± 0.7
7.42 ± 0.7
6.21 ± 0.4
4
7
19
52.3 ± 10.9
53.2 ± 10.5
50.66 ± 5.9
7.72 ± 1.49
10.4 ± 2.2
8.98 ± 1.04
{P < 0.02) for PYD only. The difference with the OA
group was significant for both parameters (P = 0.018
and P = 0.02, respectively). The PYD/DPD ratio was
6 ± 0.5. PYD and DPD were significantly (P < 0.05)
higher, by 104.1 and 69.7%, respectively, in RA
patients treated with steroids than in RA patients
without steroids (Table III). The latter were not
significantly different from the normal controls. The
PYD/DPD ratio did not vary with the steroid intake.
There was no correlation between cross-links and ESR.
DISCUSSION
The present work does not confirm the previously
reported increased urinary concentrations of PYD and
DPD m OA [13, 15].
The difference between our results and those of
previous studies does not seem to be in relation to
the controls. Our number of normal controls is
rather higher than that of previous studies, in some of
which the same control group was used repeatedly
[11,12,15]. Means and standard deviations of the
present normal control group were also close to those
of previous studies in which the same HPLC method
was used [10, 19]. There were more women and old
patients in our OA group than in the control group.
The urinary excretion of pyridinium cross-links is
similar in men and pre-menopausal women. It was also
found to be unrelated to age. An increased excretion of
PYD and DPD in peri- and post-menopausal women
was demonstrated [20, 21]. However, increasing the
number of menopaused women in our control group
would have increased the normal values accordingly.
The selection of OA patients could be an explanation
FIG. 2.—Correlation between urinary pyridinoline (PYD) and
urinary deoxypyridinoline (DPD) values in controls. Spearman test:
P< 0.001 and r = 0.76.
for our results. MacDonald et al. [15] found a higher
urinary excretion of PYD in gonOA than in coxOA
and polyOA. Astbury et al. [14] demonstrated that the
urinary excretion of pyridinium cross-links could be
related to joint damage. The present work does not
support the findings of MacDonald et al. and rather
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FIG. 3.—Urinary pyridinoline (PYD) (a) and deoxypyridinoline
(DPD) (b) values in osteoarthritis (OA) subgroups. All concen-
trations are expressed relative to urinary creatinine.
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FIG. 4.—Urinary pyridinoline (PYD) and deoxypyridinoline (DPD)
values relatively to radiographic scores. Patients were divided into
early OA (X-ray scores 1 or 2) and late OA (X-ray scores 3 or 4).
PYD and DPD increased significantly in late OA: P •= 0.003 and
P •» 0.04, respectively.
suggests an increase in some cases of polyOA. It
demonstrates that PYD and DPD excretion increased
significantly with the radiological stage of OA.
Although there was no significant difference between
the late OA subgroup and the normal group, the
selection of a larger number of patients with late OA
might have made the difference between OA and the
control significant.
The tissular topography of hydroxypyridinium
Pyridinium cross-link
RA + steroids
RA — steroids
Total
N
9
10
19
TABLE III
values (median and s.D.)
intake
PYD
78.7 ± 7.2
38.5 ± 2.3
50.6 ± 5.9
relative to steroid
DPD
12.9 ±
7.6 ±
8.8 ±
1.8
0.4
1.04
DPD/PYD
7.1 ±0.9
5.3 ± 0.3
6.1 ±0.4
cross-links has been studied in detail [1,2]. DPD could
be considered as a sensitive marker of bone
degradation since it is mostly found in bone and
dentine, and the turnover of the latter tissue is
negligible [1]. PYD is a major collagen cross-link in
bone, cartilage and other connective tissues such as
muscle and intervertebral discs [1, 22]. Although bone
resorption is probably the major source of urine
hydroxypyridinium cross-links [13, 14], the PYD/DPD
ratio may help to define collagen degradation in
cartilage relative to other tissues. In agreement with
previous studies in OA patients [10, 13], PYD and
DPD were highly correlated (r = 0.75, P < 0.001), and
the PYD/DPD ratio was unchanged. In patients with
advanced OA, both PYD and DPD were significantly
increased and the PYD/DPD ratio was also un-
changed. Thus, most probably, the observed increased
excretion of pyridinium cross-links in patients with
late OA reflects the bone erosion and/or the increased
sclerotic bone remodelling of joint epiphysis that
occurs in the advanced stages of OA. Unfortunately,
bone sclerosis was not graded in our score of OA [18].
The unchanged excretion of PYD and DPD in earlier
stage OA suggests that the markers certainly do
not reflect collagen degradation of the articular
cartilage.
An increased urinary excretion of pyridinium
cross-links has been reported in RA [12, 13, 14, 23, 24].
A small control group of RA patients was included in
this study to test the validity of our measurements. We
were able to confirm a dramatic increase in the urinary
excretion of PYD and DPD in RA patients.
Interestingly, this increase was only found in patients
treated with steroids. Since joint destruction in RA
patients was not investigated, the results suggest that
an increase in urinary PYD and DPD was related to
severe forms of RA justifying steroids, and/or with the
increased bone resorption induced by steroids.
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